Yrazines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Yrazines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Yrazines Today - Breaking & Trending Today

Scientists have developed fluorophores that are 2.4 to 20 times more intense than analogues

Scientists have developed, synthesized, and studied a series of new fluorophores, a luminous chemical compound. These are the new cyanopyrazine-based bullet systems. Studies have shown that the pr . ....

Sverdlovskaya Oblast , Egor Verbitskiy , Postovsky Institute Of Organic Synthesis Ural Branch , Ural Federal University Egor Verbitskiy , Laboratory Of Medical Chemistry , Tomsk State University , Ural Federal University Ur , Postovsky Institute , Organic Synthesis Ural Branch , Medical Chemistry , Advanced Organic Materials , Tomsk State , Organic Synthesis , Ural Branch , Russian Academy , Ural Federal University , Organic Light Emitting Diodes , Material Science , Material Developments ,

Glenmark Pharma hits 52-week high after PMS study approves Favipiravir's safety

Read more about Glenmark Pharma hits 52-week high after PMS study approves Favipiravir s safety on Business Standard. Glenmark Pharmaceuticals rose 1.21% to Rs 636.80 after the drug maker announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India. ....

Andhra Pradesh , Alok Malik , Glenmark Pharmaceuticals , Post Marketing Surveillance , India The Post Marketing Surveillance , Capital Market , Health Sciences , Covid 19 , Glenmark Pharmaceuticals , Covid 19 Pandemic In India , Pharmaceutical Industry , ஆந்திரா பிரதேஷ் , அலோக் மாலிக் , க்ளேண்மர்க் மருந்துகள் , போஸ்ட் சந்தைப்படுத்தல் கண்காணிப்பு , மூலதனம் சந்தை , ஆரோக்கியம் அறிவியல் ,

India welcomes 15 ventilators, 12,000 tablets of Favipiravir from Iceland

Read more about India welcomes 15 ventilators, 12,000 tablets of Favipiravir from Iceland on Business Standard. India on early Wednesday received a consignment of 15 ventilators, and 12000 tablets of Favipiravir from Iceland as the country combat the second wave of Covid-19 pandemic ....

United Kingdom , Arindam Bagchi , Union Ministry Of Health , Spokesperson Ministry Of External Affairs , Spokesperson Ministry , External Affairs , Union Ministry , Family Welfare , Ontemporary History , Covid 19 , Ovid 19 Pandemic , Ocial Media Amp Networking , Arindam Bagchi , Health Infrastructure , United Kingdom , Ministry Of , ஒன்றுபட்டது கிஂக்டம் , அரிந்தம் பாகி , தொழிற்சங்கம் அமைச்சகம் ஆஃப் ஆரோக்கியம் , வெளிப்புறம் வாழ்க்கைத்தொழில்கள் , தொழிற்சங்கம் அமைச்சகம் , குடும்பம் நலன்புரி , விட் சர்வதேச பரவல் ,

Bal Pharma hits the roof on launching favipiravir formulation

Bal Pharma hit an upper circuit of 5% at Rs 98.50 after the company announced the launch of favipiravir formulation into Indian market, under the brand name BALflu.
Favipiravir is an emerging anti-viral drug used for patients with mild to moderate COVID-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus.
BALflu (favipiravir) is a broad-spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, filovirus, west nile virus, food & mouth disease virus and lassa virus. ....

Shailesh Siroya , Bal Pharma , Drug Controller General , Capital Market , Physical Sciences , Antiviral Drugs , Chemical Compounds , Covid 19 , K 05 , Harmaceuticals Nec , Bal Pharma , Director Of The Company , West Nile , Influenza Virus , பால் பார்மா , மருந்து கட்டுப்படுத்தி ஜநரல் , மூலதனம் சந்தை ,

Bharat Parenterals jumps on bagging manufacturing licence for Favipiravir

Bharat Parenterals was locked in an upper circuit of 5% at Rs 406.20 after the pharma company said it received the regulatory license and authorization for the manufacturing and marketing Favipiravir oral suspension 100mg/ml.Bharat Parenterals has received the license and authorization from Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO), New Delhi for the manufacturing and marketing of Favipiravir oral suspension 100mg/mi, which will be used for treatment of COVID 19 disease.
The product patent has been already filed under fast track approval. Bharat Parenterals is the first Indian company to receive the manufacturing and marketing approval for Favipiravir oral suspension 100mg/mi. ....

New Delhi , Bharat Parenterals , Ministry Of Health , Central Drugs Standard Control Organisation , Drugs Controller General , Family Welfare , Capital Market , Physical Sciences , Chemical Compounds , Covid 19 , Harmaceuticals Nec , Government Of India , Drugs Controller General , Reatment Of Covid 19 Disease , புதியது டெல்ஹி , பாரத் பெற்றோர் , அமைச்சகம் ஆஃப் ஆரோக்கியம் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , குடும்பம் நலன்புரி , மூலதனம் சந்தை ,